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Abstract: 
 
Mast cells and basophils express high amounts of FcϵRI. In basophils the concentration of anti-
IgE or antigen required for maximal histamine release through FcϵRI varies among donors, a 
concept termed “releasability.” Some donors fail to release histamine in response to any 
concentration of IgE-mediated stimulus (nonreleaser)1, 2, 3, 4 and were subsequently found to lack 
the protein tyrosine kinase Syk.5 Although the nonreleaser phenoytpe is common (ie, present in 
10% to 20% of all donors), it is not known whether mast cells exhibit a similar IgE-mediated 
nonresponsiveness. We report here a lung mast cell preparation that did not respond to IgE-
mediated stimuli. 
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Article: 
 
To the Editor: 
 
Mast cells and basophils express high amounts of FcϵRI. In basophils the concentration of anti-
IgE or antigen required for maximal histamine release through FcϵRI varies among donors, a 
concept termed “releasability.” Some donors fail to release histamine in response to any 
concentration of IgE-mediated stimulus (nonreleaser)1, 2, 3, 4 and were subsequently found to lack 
the protein tyrosine kinase Syk.5 Although the nonreleaser phenoytpe is common (ie, present in 
10% to 20% of all donors), it is not known whether mast cells exhibit a similar IgE-mediated 
nonresponsiveness. We report here a lung mast cell preparation that did not respond to IgE-
mediated stimuli. 
 
Mast cells were dispersed from human lung tissue and enriched as described previously.6 This 
donor was undergoing a thoracotomy for lung cancer and was not receiving steroid therapy. 
These studies were approved by the Human Studies Internal Review Board at Virginia 
Commonwealth University. Mast cells were positively selected with mouse anti-c-kit receptor 
antibodies (YB5B8, a gift from Leonie Ashman) and bead-conjugated anti-mouse antibodies, as 
per the manufacturer's instructions (Miltenyi, Auburn, Calif). A total of 3.2 × 107 cells were 
isolated from 30 g of tissue. The purity of mast cells was 76%, as assessed with toluidine blue 
staining. The mast cells were cultured at 1 × 106 cells/mL in RPMI medium supplemented with 
10% CPSR-1 (Sigma, St Louis, Mo), 10 μmol/L HEPES, 50 μmol/L 2-mercaptoethanol, 4 
mmol/L L-glutamine, 1× MEM amino acids, 1× vitamin solution, 100 U/mL penicillin, 100 
μg/mL streptomycin (Gibco, Gaithersburg Md), and 100 ng/mL recombinant human stem cell 
factor (Biosource, Camarillo, Calif). Nitrophenacetyl-specific IgE (NP-IgE; 5 μg/mL) was added 
on day 2 of culture. After 3 days, we performed FACS analysis by using the mouse anti-human 
FcϵRI α chain (22E7, gift from Dr J. Kochan) and c-kit receptor antibodies. These mast cells 
expressed high amounts of FcϵRI and the c-kit receptor (data not shown). No obvious 
morphologic differences were observed by means of light microscopy when comparing 
toluidine-stained mast cells from cells responsive to IgE-mediated stimuli (not shown). 
 
 
Fig. 1. A, Specific impairment of FcϵRI-dependent degranulation in lung mast cells. Data are from 1 experiment and 
are representative of 2 other experiments, each done in duplicate and performed with mast cells (mean ± SEM, n = 
3). ND, Not done. B, Isolation procedure for lung mast cells does not induce FcϵRI nonresponsiveness. 
 
Initial degranulatory experiments (routinely performed in our laboratory)5, 6, 7, 8 with IgE-
sensitized cells cultured for 3 days showed this preparation did not respond to IgE stimulus (not 
shown). We hypothesized that these mast cells were defective in their ability to degranulate in 
response to IgE-mediated stimulus. To test this hypothesis, we used peripheral blood basophils 
from a separate known releaser donor in parallel with the lung mast cells to ensure all reagents 
were working properly. IgE-sensitized lung mast cells or freshly isolated basophils (sensitized 
with NP-IgE for 4 hours)7 were washed and challenged with different concentrations of anti-IgE 
or NP-BSA, A23187 (500 ng/mL), or no stimulus (spontaneous) for 30 minutes. The 
supernatants were measured for histamine release by using a kit from Beckman-Coulter 
(Marseille, France), and the percentage of histamine release was calculated as described 
previously.8 As expected, basophils released histamine in response to antigen or anti-IgE 
antibodies. However, by using identical reagents and experimental conditions, the lung mast 
cells failed to release histamine in response to any concentration of antigen or anti-IgE (Fig 1, A). 
 
In addition, no β-hexosiminidase release was detected in the supernatants of the mast cells (data 
not shown). Although FcϵRI-induced secretion was absent, the mast cells secreted normally 
when challenged with Ca2+ionophore, which induces secretion in part by direct effects on 
cytoplasmic Ca2+ levels. The methods for mast cell purification from the tissue did not cause IgE 
nonresponsiveness because a previous mast cell preparation (84% purity; isolated, sensitized, 
and activated as above) released histamine when challenged with varying concentrations of 
antigen (Fig 1, B ). Therefore these mast cells had a specific defect in their IgE-mediated signal 
transduction pathway because their ability to degranulate remained intact. 
 
We have not detected other mast cell preparations that did not degranulate in response to FcϵRI-
mediated stimulus (n = 4). We conclude that the mast cells in these experiments were defective 
in their IgE-mediated signaling and might reflect a heretofore unknown mast cell nonreleaser 
phenotype. More studies are needed to confirm these preliminary findings. 
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